Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has maintained a Neutral rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and raised the price target from $2 to $3.
March 06, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska maintains a Neutral rating on Rigel Pharmaceuticals but raises the price target from $2 to $3.
The increase in price target from $2 to $3 by a reputable analyst suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, suggesting limited upside potential.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100